These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36277321)

  • 1. Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.
    Rohant N; Kennedy JL
    Heart Int; 2021; 15(1):42-48. PubMed ID: 36277321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
    Rodriguez R; Kaluzna SD
    Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.
    Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients.
    Balan I; Khayo T; Sultanova S; Lomakina Y
    Cureus; 2021 Aug; 13(8):e17118. PubMed ID: 34527497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure.
    Kaplinsky E
    Drugs Context; 2020; 9():. PubMed ID: 32165892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A; Salvo M
    Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
    Aziri B; Begic E; Jankovic S; Mladenovic Z; Stanetic B; Kovacevic-Preradovic T; Iglica A; Mujakovic A
    ESC Heart Fail; 2023 Jun; 10(3):1499-1530. PubMed ID: 36967133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
    March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
    Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.
    Kubota Y; Shimizu W
    JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
    Siamashvili M; Davis SN
    Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.
    Shah KS; Fang JC
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():109-120. PubMed ID: 34516288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy.
    Naito R; Kasai T
    World J Cardiol; 2021 Sep; 13(9):464-471. PubMed ID: 34621491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y; Wei Y; Li D; Pu J; Ding H; Zhang X
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):4-14. PubMed ID: 36607775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.